Drugs that contain Omaveloxolone
1. List of Skyclarys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9670147 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(5 years from now) | |
| US8124799 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Dec, 2029
(6 years from now) | |
| US8993640 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(9 years from now) | |
| US9701709 | REATA PHARMS | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440854 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
Apr, 2029
(5 years from now) | |
| US11091430 | REATA PHARMS | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
Apr, 2029
(5 years from now) | |
Do you want to check out SKYCLARYS patents from before 2022?
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 28, 2030 |
| New Chemical Entity Exclusivity (NCE) | Feb 28, 2028 |
NCE-1 date: 2027-02-28
Market Authorisation Date: 28 February, 2023
Treatment: Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older
Dosage: CAPSULE;ORAL
More Information on Dosage
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic